REMARKS

I. Status

The Office Action indicates claims 1-34 to be pending in this Application. With this response, claims 1, 7, 12, 15, 18, 19, 21, 24, and 27-30 are amended, claims 11 and 17 are canceled without prejudice or disclaimer, and claim 35 is added. No new matter has been added.

Claims 1, 7, 12, 15, 18, 19, 21, 24, and 27-30 are objected to.

Claims 1, 5, 12, 14, and 31 are rejected under 35 U.S.C. 103(a) as being unpatentable over Banginwar (U.S. Patent No. 6,611,863) in view of Lakshman (U.S. Patent No. 6,341,130).

Claims 2, 4, 6, and 13 are rejected under 35 U.S.C. 103(a) as being unpatentable over Banginwar and Lakshman in view of Duvall (U.S. Patent No. 5,884,033).

Claim 3 is rejected under 35 U.S.C. 103(a) as being unpatentable over Banginwar and Lakshman in view of Krumel (U.S. Patent No. 7,013,482).

Claims 7, 11, and 15 are rejected under 35 U.S.C. 103(a) as being unpatentable over Banginwar in view of Haggerty (U.S. Patent No. 6,331,983).

Claims 8 and 10 are rejected under 35 U.S.C. 103(a) as being unpatentable over Banginwar and Haggerty in view of Duvall.

Claims 9, 16, and 17 are rejected under 35 U.S.C. 103(a) as being unpatentable over Banginwar and Haggerty in view of Krumel.

Claims 21-23 and 33 are rejected under 35 U.S.C. 103(a) as being unpatentable over Banginwar and Lakshman in view of Wootton (U.S. Patent No. 6,128,298).

Claims 24-26 are rejected under 35 U.S.C. 103(a) as being unpatentable over

Banginwar, Lakshman, and Wootton in view of Haggerty.

Claims 18, 29, and 32 are rejected under 35 U.S.C. 103(a) as being unpatentable over Haggerty in view of Wootton.

Claim 27 is rejected under 35 U.S.C. 103(a) as being unpatentable over Krumel in view of Wootton.

Claims 19, 20, 28, 30, and 34 are rejected under 35 U.S.C. 103(a) as being unpatentable over Duvall in view of Wootton.

Claims 1, 7, 12, 15, 18, 19, 21, 24, 27-30, and 35 are independent.

II. Objection to the Claims

The Office Action objects to claims 1, 7, 12, 15, 18, 19, 21, 24, and 27-30, the Office Action stating that:

"[c]laims 1, 7, 12, 15, 18-19, 21, 24, 27-30 are objected to as being missing brief description of nature and intended use of article in which the design is embodied, see 37 CFR 1.154 (b)(1)" (see Office Action p. 3).

However, Applicants respectfully observe that 37 CFR 1.154(b)(1) appears to deal with the sections that should be included in the <u>specification</u> of a <u>design</u> patent application:

"37 CFR 1.154 Arrangement of application elements in a design application

- ... (b) The <u>specification</u> should <u>include the following</u> <u>sections</u> in order:
- (1) Preamble, stating the name of the applicant, title of the design, and a brief description of the nature and intended use of the article in which the design is embodied" (see 37 CFR 1.154; emphasis added).

Applicants respectfully submit that claims 1, 7, 12, 15, 18, 19, 21, 24, and 27-30 at least with the amendments herewith are in compliance with all appropriate requirements, and respectfully request that the objection be withdrawn.

III. <u>Amendment of Independent Claims 1, 7, 12, 15, 18, 19, 21, 24, and 27-30 and Addition of Independent Claim 35</u>

With this response independent claims 1, 7, 12, 15, 18, 19, 21, 24, and 27-30 are amended and independent claim 35 is added. No new matter has been added.

Applicants respectfully submit that the cited references, taken individually or in combination, fail, for example, to disclose, teach, or suggest the functionality regarding the "service information table created in the client machine," the "service information table created in a receiving node," and the "service information table created in the terminal" set forth in claims 1, 7, 12, 15, 18, 19, 21, 24, 27-30, and 35 with the amendments herewith (emphasis added).

In view of at least the foregoing, Applicants respectfully submit that claims 1, 7, 12, 15, 18, 19, 21, 24, 27-30, and 35 at least with the amendments herewith, as well as those claims that depend therefrom, are in condition for allowance.

IV. <u>Dependent Claim Rejections</u>

Applicants do not believe it is necessary at this time to further address the rejections of the dependent claims as Applicants believe that the foregoing places the independent claims in condition for allowance. Applicants, however, reserve the right to further

address those rejections in the future should such a response be deemed necessary and appropriate.

V. <u>Additional Matters</u>

Applicants note that all claims stand rejected in United States Patent Application Serial No. 10/226,883 (filed August 23, 2002), which is a continuation-in-part of the present application.

(Continued on next page)

CONCLUSION

Applicants respectfully submit that this application is in condition for allowance for which action is earnestly solicited.

If a telephone conference would facilitate prosecution of this application in any way, the Examiner is invited to contact the undersigned at the number provided.

AUTHORIZATION

The Commissioner is hereby authorized to charge any fees which may be required for this submission, or credit any overpayment to Deposit Account No. 13-4500, Order No. 4208-4045.

Furthermore, in the event that an extension of time is required, the Commissioner is requested to grant a petition for that extension of time which is required to make this response timely and is hereby authorized to charge any fee for such an extension of time or credit any overpayment for an extension of time to the above-noted Deposit Account and Order No.

Respectfully submitted,

MORGAN & FINNEGAN, L.L.P.

Mailing Address:

Dated: January 30, 2008

MORGAN & FINNEGAN, L.L.P. 3 World Financial Center New York, New York 10281-2101 (212) 415-8700 (212) 415-8701 (Fax)

By:

Angus R. Gill

Registration No. 51,133